Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer - Summary - MDSpire
Advertisement
Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer
To assess the risks and long-term outcomes of completing the full regimen of perioperative chemoimmunotherapy versus non-completion in patients with resectable non-small cell lung cancer.
Key Findings:
No significant differences in recurrence-free survival (P = 0.85) or overall survival (P = 0.34) between completed and non-completed groups.
Positive pathological nodal status was an independent predictor of recurrence.
Completion status did not significantly predict recurrence (adjusted hazard ratio 1.14, 95% CI 0.24-5.50, P = 0.87).
The completed group experienced a higher incidence of any-grade adverse events, but no significant increase in Grade 3/4 adverse events.
Subgroup analysis indicated a notable recurrence benefit from completion in patients aged <65 years and with ECOG score 0.
Interpretation:
Remove unsupported conclusions and focus on summarizing the findings.
Limitations:
The study is retrospective and may be subject to biases.
Limited follow-up duration may affect the long-term outcome assessment.
Conclusion:
Revise to eliminate recommendations and focus on the need for further studies as stated in the source.
